The path of least resistance: aggressive or moderate treatment?

Roger D Kouyos¹, C Jessica E Metcalf², Ruthie Birger³, Eili Y Klein⁴, Pia Abel zur Wiesch⁵, Peter Ankomah⁶, Nimalan Arinaminpathy⁷, Tiffany L Bogich⁸, Sebastian Bonhoeffer⁹, Charles Brower¹⁰, Geoffrey Chi-Johnston¹¹, Ted Cohen⁵, Troy Day¹², Bryan Greenhouse¹³, Silvie Huijben¹⁴, Joshua Metlay¹⁵, Nicole Mideo¹⁶, Laura C Pollitt¹⁷, Andrew F Read¹⁸, David L Smith¹⁹, Claire Standley²⁰, Nina Wale²¹, Bryan Grenfell⁸

Affiliations

¹ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
² Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Department of Zoology, Oxford University, Oxford, UK.
³ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA rbirger@princeton.edu.
⁴ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Center for Advanced Modeling, Department of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA.
⁵ Division of Global Health Equity, Brigham and Women's Hospital and Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
⁶ Department of Biology, Emory University, Atlanta, GA, USA.
⁷ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
⁸ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Fogarty International Center, National Institutes of Health, Bethesda, MD, USA.
⁹ Institute of Integrative Biology ETH Zurich, Zurich, Switzerland.
¹⁰ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Center for Disease Dynamics, Economics & Policy, Washington, DC, USA.
¹¹ Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
¹² Departments of Mathematics and Biology, Queen's University, Kingston, Ontario, Canada.
¹³ Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, VA, USA.
¹⁴ Barcelona Centre for International Health Research, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
¹⁵ General Medicine Division, Massachusetts General Hospital, Boston, MA, USA.
¹⁶ Department of Ecology and Evolutionary Biology, University of Toronto, Toronto, Ontario, Canada.
¹⁷ Centre for Infectious Disease Dynamics, The Pennsylvania State University, University Park, State College, PA, USA Departments of Biology and Entomology, The Pennsylvania State University, University Park, State College, PA, USA Centre for Immunology, Infection and Evolution, University of Edinburgh, Edinburgh, UK.
¹⁸ Centre for Infectious Disease Dynamics, The Pennsylvania State University, University Park, State College, PA, USA Departments of Biology and Entomology, The Pennsylvania State University, University Park, State College, PA, USA Fogarty International Center, National Institutes of Health, Bethesda, MD, USA.
¹⁹ Department of Zoology, Oxford University, Oxford, UK.
²⁰ Department of Health Policy, George Washington University, Washington, DC, USA.
²¹ Centre for Infectious Disease Dynamics, The Pennsylvania State University, University Park, State College, PA, USA Departments of Biology and Entomology, The Pennsylvania State University, University Park, State College, PA, USA.

PMID: 25253451
PMCID: PMC4211439
DOI: 10.1098/rspb.2014.0566

The path of least resistance: aggressive or moderate treatment?

Roger D Kouyos et al. Proc Biol Sci. 2014.

. 2014 Nov 7;281(1794):20140566.

doi: 10.1098/rspb.2014.0566.

Authors

Affiliations

¹ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
² Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Department of Zoology, Oxford University, Oxford, UK.
³ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA rbirger@princeton.edu.
⁴ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Center for Advanced Modeling, Department of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA.
⁵ Division of Global Health Equity, Brigham and Women's Hospital and Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
⁶ Department of Biology, Emory University, Atlanta, GA, USA.
⁷ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
⁸ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Fogarty International Center, National Institutes of Health, Bethesda, MD, USA.
⁹ Institute of Integrative Biology ETH Zurich, Zurich, Switzerland.
¹⁰ Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA Center for Disease Dynamics, Economics & Policy, Washington, DC, USA.
¹¹ Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
¹² Departments of Mathematics and Biology, Queen's University, Kingston, Ontario, Canada.
¹³ Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, VA, USA.
¹⁴ Barcelona Centre for International Health Research, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
¹⁵ General Medicine Division, Massachusetts General Hospital, Boston, MA, USA.
¹⁶ Department of Ecology and Evolutionary Biology, University of Toronto, Toronto, Ontario, Canada.
¹⁷ Centre for Infectious Disease Dynamics, The Pennsylvania State University, University Park, State College, PA, USA Departments of Biology and Entomology, The Pennsylvania State University, University Park, State College, PA, USA Centre for Immunology, Infection and Evolution, University of Edinburgh, Edinburgh, UK.
¹⁸ Centre for Infectious Disease Dynamics, The Pennsylvania State University, University Park, State College, PA, USA Departments of Biology and Entomology, The Pennsylvania State University, University Park, State College, PA, USA Fogarty International Center, National Institutes of Health, Bethesda, MD, USA.
¹⁹ Department of Zoology, Oxford University, Oxford, UK.
²⁰ Department of Health Policy, George Washington University, Washington, DC, USA.
²¹ Centre for Infectious Disease Dynamics, The Pennsylvania State University, University Park, State College, PA, USA Departments of Biology and Entomology, The Pennsylvania State University, University Park, State College, PA, USA.

PMID: 25253451
PMCID: PMC4211439
DOI: 10.1098/rspb.2014.0566

Abstract

The evolution of resistance to antimicrobial chemotherapy is a major and growing cause of human mortality and morbidity. Comparatively little attention has been paid to how different patient treatment strategies shape the evolution of resistance. In particular, it is not clear whether treating individual patients aggressively with high drug dosages and long treatment durations, or moderately with low dosages and short durations can better prevent the evolution and spread of drug resistance. Here, we summarize the very limited available empirical evidence across different pathogens and provide a conceptual framework describing the information required to effectively manage drug pressure to minimize resistance evolution.

Keywords: drug resistance; evolution; treatment strategies.

PubMed Disclaimer

Figures

**Figure 1.**
The curve defining resistance evolution as a function of drug pressure. The x-axis is the possible range of drug pressures, measured as either drug dosage, or duration of treatment, with the realistic/neutral range of drug pressures highlighted in green, showing (a) a case where aggressive chemotherapy is likely to be optimal, as there is a level of drug pressure for which the pathogen can be completely cleared and (b) a case where moderate chemotherapy is likely to be optimal for managing resistance, as there is no realistic degree of drug pressure that can clear the pathogen. The y-axis is the rate of resistance emergence, or the inverse of time from introduction of treatment until a resistant strain is established. Numbers 1–3 refer to the three qualitative evolutionary regimes: no evolution of resistance because selection is too weak (1), no evolution of resistance because pathogen cannot replicate (2), maximal speed of resistance evolution (3).

See this image and copyright information in PMC

References

1. Hughes JM. 2011. Preserving the lifesaving power of antimicrobial agents. JAMA 305, 1027–1028. (10.1001/jama.2011.279) - DOI - PubMed
1. Walsh TR, Toleman MA. 2012. The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J. Antimicrob. Chemother. 67, 1–3. (10.1093/jac/dkr378) - DOI - PubMed
1. Goossens H, Ferech M, Vanderstichele R, Elseviers M. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 358, 718–723. - PubMed
1. Bronzwaer SL, Cars O, Buchholz U, Molstad S, Goettsch W, Veldhuijzen IK, Kool JL, Sprenger MJ, Degener JE. 2002. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg. Infect. Dis. 8, 278–282. (10.3201/eid0803.010192) - DOI - PMC - PubMed
1. Ehrlich P. 1913. Address in pathology, on chemiotherapy: delivered before the Seventeenth International Congress of Medicine. Br. Med. J. 2, 353–359. (10.1136/bmj.2.2746.353) - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The path of least resistance: aggressive or moderate treatment?

Affiliations

The path of least resistance: aggressive or moderate treatment?

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical